Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States

The tubeless, automated insulin delivery system (AID) (Omnipod 5 Automated Insulin Delivery System, Insulet Corporation) is cleared for the treatment of individuals aged 2 years and older with type 1 diabetes. Clinical study data have shown that the use of this device is safe and results in improved...

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2023-07, Vol.29 (7), p.807-817
Main Authors: Biskupiak, Joseph E, Ramos, Mafalda, Levy, Carol J, Forlenza, Greg, Hopley, Colin, Boyd, Jennifer, Swift, Dan, Lamotte, Mark, Brixner, Diana I
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The tubeless, automated insulin delivery system (AID) (Omnipod 5 Automated Insulin Delivery System, Insulet Corporation) is cleared for the treatment of individuals aged 2 years and older with type 1 diabetes. Clinical study data have shown that the use of this device is safe and results in improved glucose control (lower hemoglobin A1c and less hypoglycemia). The current study demonstrated that, as compared with standard of care (SoC), the tubeless system can be considered cost-effective and, in some scenarios, demonstrates cost savings and health gain in the United States.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2023.22331